<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006972" GROUP_ID="ENDOC" ID="289607050915210415" MERGED_FROM="" MODIFIED="2008-11-20 14:02:02 +0100" MODIFIED_BY="Gudrun Paletta" REVIEW_NO="NS07" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="2.2">
<COVER_SHEET MODIFIED="2008-11-20 14:02:02 +0100" MODIFIED_BY="Gudrun Paletta">
<TITLE>High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism</TITLE>
<CONTACT MODIFIED="2008-11-20 14:02:02 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="11758" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sze May</FIRST_NAME><LAST_NAME>Ng</LAST_NAME><EMAIL_1>ngszemay@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>School of Reproductive and Developmental Medicine</DEPARTMENT><ORGANISATION>University of Liverpool, 1st Floor</ORGANISATION><ADDRESS_1>Liverpool Women's Hospital</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 702 4111</PHONE_1><PHONE_2>+ 44 151 702 4024</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-20 14:02:02 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="11758" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sze May</FIRST_NAME><LAST_NAME>Ng</LAST_NAME><EMAIL_1>ngszemay@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>School of Reproductive and Developmental Medicine</DEPARTMENT><ORGANISATION>University of Liverpool, 1st Floor</ORGANISATION><ADDRESS_1>Liverpool Women's Hospital</ADDRESS_1><ADDRESS_2>Crown Street</ADDRESS_2><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><REGION>Merseyside</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 702 4111</PHONE_1><PHONE_2>+ 44 151 702 4024</PHONE_2></ADDRESS></PERSON><PERSON ID="7588F3F382E26AA201AA8B4220317E5A" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dhullipala</FIRST_NAME><LAST_NAME>Anand</LAST_NAME><POSITION>Lecturer</POSITION><EMAIL_1>dhullipala.anand@ggc.scot.nns.uk</EMAIL_1><ADDRESS><DEPARTMENT>Consultant Neonatologist</DEPARTMENT><ORGANISATION>Quenn Mother's Hospital</ORGANISATION><ADDRESS_1>Dalnair Street</ADDRESS_1><CITY>Glasgow</CITY><ZIP>G3 8SJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 141 2010573</PHONE_1></ADDRESS></PERSON><PERSON ID="5AF2A5F182E26AA201D1E76562458A04" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Alan</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Weindling</LAST_NAME><POSITION>Professor of Perinatal Medicine</POSITION><ADDRESS><DEPARTMENT>School of Reproductive and Developmental Medicine</DEPARTMENT><ORGANISATION>University of Liverpool</ORGANISATION><ADDRESS_1>Crown Street</ADDRESS_1><CITY>Liverpool</CITY><ZIP>L8 7SS</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-11 17:34:43 +0100" MODIFIED_BY="Bernd Richter">
<UP_TO_DATE>
<DATE DAY="31" MONTH="7" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="7" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="11" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-05 17:08:39 +0100" MODIFIED_BY="Bernd Richter">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-05 17:08:39 +0100" MODIFIED_BY="Bernd Richter">
<DATE DAY="11" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-05-27 13:34:45 +0200" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-10 21:29:32 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-10 15:57:31 +0100" MODIFIED_BY="Bernd Richter">
<TITLE MODIFIED="2008-04-17 13:53:38 +0200" MODIFIED_BY="[Empty name]">High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-10 15:57:31 +0100" MODIFIED_BY="Bernd Richter">
<P>Congenital hypothyroidism is a condition that affects infants from birth and results from a missing or abnormally developed thyroid gland, abnormal production of thyroid hormones or a failure of the pituitary gland to stimulate thyroid hormone production. It affects approximately 1 in 3000 to 4000 newborn infants and early diagnosis and treatment is very important to achieve a good outcome.Treatment of congenital hypothyroidism consists of a daily dose of thyroid hormone (thyroxine). However, the initial dose of thyroxine required to improve outcomes for infants with this condition is unclear and has been the subject of several studies. Some studies have suggested that when infants with congenital hypothyroidism are treated with a higher dose of thyroxine compared with the standard dose, this results in earlier normalisation of the their thyroid hormones and leads to better developmental outcome and intelligence.</P>
<P>There is currently only one study reporting on 47 babies that fulfils our review criteria and compares different high dose versus low dose of initial replacement thyroxine for the treatment of congenital hypothyroidism. There is not enough evidence to suggest that a high dose is more beneficial than a low dose therapy. Growth and adverse effects were not reported in the included study. There should be more randomised controlled trials to assess the effects of high versus low dose of initial thyroid hormone replacement for congenital hypothyroidism.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-10 16:09:15 +0100" MODIFIED_BY="Bernd Richter">
<ABS_BACKGROUND MODIFIED="2008-11-10 15:18:13 +0100" MODIFIED_BY="Bernd Richter">
<P>Congenital hypothyroidism (CHT) affects approximately one in 3000 to 4000 infants. CHT is one of the most common preventable causes of learning difficulties. Optimal management of CHT requires early diagnosis and prompt treatment to avoid abnormal neurodevelopmental outcome.  One of the main issues in the management of CHT relates to the initial dose of levothyroxine to be used in order to achieve optimal results in terms of intellectual development. Currently, it remains unclear whether high dose thyroid hormone replacement is more effective than low dose in the treatment of CHT. Further research is required to determine an appropriate dose that improves mental and psychomotor developmental outcomes.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-10-09 21:40:27 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effects of high versus low dose of initial thyroid hormone replacement for congenital hypothyroidism.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-10 15:16:59 +0100" MODIFIED_BY="Bernd Richter">
<P>Randomised controlled trials were identified by searching <I>The Cochrane Library</I>, MEDLINE and EMBASE and reference lists of published papers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-11-10 15:19:01 +0100" MODIFIED_BY="Bernd Richter">
<P>Randomised controlled clinical trials investigating the effects of high versus low dose of initial thyroid hormone replacement for congenital hypothyroidism were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-11-10 15:19:14 +0100" MODIFIED_BY="Bernd Richter">
<P>Both authors independently selected trials, assessed risk of bias and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-10 15:56:47 +0100" MODIFIED_BY="Bernd Richter">
<P>The initial search identified 1014 records which identified 13 publications for further examination. After screening the full text of the 13 selected papers, only one study evaluating 47 babies finally met the inclusion criteria. Using the same cohort at two different time periods, the study investigated the effects of high versus low dose thyroid hormone replacement in relation to (1) time taken to achieve euthyroid status and (2) neurodevelopmental outcome. The study reported that a high dose is more effective in rising serum thyroxine and free thyroxine concentrations to the target range and earlier normalisation of thyroid stimulating hormone compared to a lower dose. Similarly, full scale intelligence quotient was noted to be significantly higher in children who received the high dose compared to the lower dose. However, the verbal intelligence quotient and performance intelligence quotient were similar in both groups. Growth and adverse effects were not reported in the included trial.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-10 16:09:15 +0100" MODIFIED_BY="Bernd Richter">
<P>There is currently only one randomised controlled trial evaluating the effects of high versus low dose of initial thyroid hormone replacement for CHT. There is inadequate evidence to suggest that a high dose is more beneficial compared to a low dose initial thyroid hormone replacement in the treatment of CHT. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-10 21:29:32 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-10 21:28:12 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2008-11-10 15:57:45 +0100" MODIFIED_BY="Bernd Richter">
<P>Congenital hypothyroidism (CHT) is one of the most common preventable causes of learning difficulties with a prevalence of approximately 1 in 3000 to 4000 births (<LINK REF="REF-AAP-1993" TYPE="REFERENCE">AAP 1993</LINK>; <LINK REF="REF-LaFranchi-1999" TYPE="REFERENCE">LaFranchi 1999</LINK>). In the majority of cases, the disorder is permanent and results from an abnormality in thyroid gland development (dysgenesis or agenesis) or a defect in thyroid hormonogenesis but rarely it can be due to pituitary or hypothalamic abnormality (central or secondary/tertiary hypothyroidism) (<LINK REF="REF-AAP-1993" TYPE="REFERENCE">AAP 1993</LINK>; <LINK REF="REF-Song-2001" TYPE="REFERENCE">Song 2001</LINK>). Occasionally, the altered neonatal thyroid function is transient, due to the transplacental passage of maternal medication, maternal blocking antibodies, or iodine deficiency or excess (<LINK REF="REF-Brown-1996" TYPE="REFERENCE">Brown 1996</LINK>; <LINK REF="REF-Calaciura-2002" TYPE="REFERENCE">Calaciura 2002</LINK>; <LINK REF="REF-Haddow-1999" TYPE="REFERENCE">Haddow 1999</LINK>).</P>
<P>CHT can result in poor cognitive development, school delay and behavioural problems (<LINK REF="REF-Gruters-2002" TYPE="REFERENCE">Gruters 2002</LINK>; <LINK REF="REF-Oerbeck-2003" TYPE="REFERENCE">Oerbeck 2003</LINK>; <LINK REF="REF-Rovet-2002" TYPE="REFERENCE">Rovet 2002</LINK>). Routine screening programmes have resulted in early diagnosis and treatment with levothyroxine (L-T4) which in turn have led to a marked improvement in overall prognosis (<LINK REF="REF-Hulse-1984" TYPE="REFERENCE">Hulse 1984</LINK>; <LINK REF="REF-Murphy-1986" TYPE="REFERENCE">Murphy 1986</LINK>). The age at which treatment is started, the initial dose and time take to achieve and maintain the target ranges for thyroxine (T4) and thyroid stimulating hormone (TSH) play an important role in achieving normal outcome (<LINK REF="REF-Grant-1992" TYPE="REFERENCE">Grant 1992</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-11-10 21:28:12 +0100" MODIFIED_BY="[Empty name]">
<P>There are varying reports for follow-up studies of intellectual development in children with CHT treated early (<LINK REF="REF-Heyerdahl-1991" TYPE="REFERENCE">Heyerdahl 1991</LINK>; <LINK REF="REF-Murphy-1986" TYPE="REFERENCE">Murphy 1986</LINK>; <LINK REF="REF-Salerno-1999" TYPE="REFERENCE">Salerno 1999</LINK>). It is recommended that early normalisation of TSH is one of the aims in the management of CHT (<LINK REF="REF-Heyerdahl-1991" TYPE="REFERENCE">Heyerdahl 1991</LINK>; <LINK REF="REF-Murphy-1986" TYPE="REFERENCE">Murphy 1986</LINK>; <LINK REF="REF-Ng-2004" TYPE="REFERENCE">Ng 2004</LINK>). Studies have shown that delayed TSH normalisation was significantly related to plasma T4 levels and dosage of L-T4, suggesting that this may be due to undertreatment in the initial stage (<LINK REF="REF-Abusrewil-1988" TYPE="REFERENCE">Abusrewil 1988</LINK>; <LINK REF="REF-Brown-1996" TYPE="REFERENCE">Brown 1996</LINK>; <LINK REF="REF-Heyerdahl-1991" TYPE="REFERENCE">Heyerdahl 1991</LINK>). The initial starting dose of L-T4 (conventional dose of 5 to 10 &#956;g/kg/day versus high dose 10 to 15 &#956;g/kg/day) has been the subject of previous studies (<LINK REF="STD-Campos-1995" TYPE="STUDY">Campos 1995</LINK>; <LINK REF="STD-Dubuis-1996" TYPE="STUDY">Dubuis 1996</LINK>; <LINK REF="STD-Salerno-2002" TYPE="STUDY">Salerno 2002</LINK>). Initial doses of L-T4 of 10 to 15 &#956;g/kg/day have been reported to result in normalisation within three weeks whereas doses of 8 &#956;g/kg/day result in normalisation within 6 to 8 weeks (<LINK REF="STD-Campos-1995" TYPE="STUDY">Campos 1995</LINK>; <LINK REF="REF-Fisher-1989" TYPE="REFERENCE">Fisher 1989</LINK>; <LINK REF="REF-Germak-1990" TYPE="REFERENCE">Germak 1990</LINK>; <LINK REF="REF-Rovet-1995" TYPE="REFERENCE">Rovet 1995</LINK>). In addition, early high dose L-T4 has been reported to close the developmental gap and normalise intelligence quotient (IQ) (<LINK REF="STD-Dubuis-1996" TYPE="STUDY">Dubuis 1996</LINK>; <LINK REF="STD-Bongers_x002d_Schokking-2000" TYPE="STUDY">Bongers-Schokking 2000</LINK>; <LINK REF="REF-Rovet-1995" TYPE="REFERENCE">Rovet 1995</LINK>; <LINK REF="REF-Simoneau_x002d_Roy-2004" TYPE="REFERENCE">Simoneau-Roy 2004</LINK>). A starting L-T4 dose of 10 to 15 mcg/kg/day is currently recommended by the European Society for Paediatric Endocrinology (ESPE) (<LINK REF="REF-Working-group-1999" TYPE="REFERENCE">Working group 1999</LINK>).</P>
<P>The recommended goal of therapy is to normalise blood T4 concentrations within 2 to 3 weeks and blood TSH concentrations within one month (<LINK REF="REF-AAP-1993" TYPE="REFERENCE">AAP 1993</LINK>; <LINK REF="REF-Song-2001" TYPE="REFERENCE">Song 2001</LINK>). Outcome studies by Song et al showed that children with CTH who took the longest time to normalise their thyroid hormones had greater difficulty in tasks of attention and memory compared with children who normalised their thyroid function earlier (<LINK REF="REF-Song-2001" TYPE="REFERENCE">Song 2001</LINK>). Although a lower initial dose (less than 10 µg/kg/day) of L-T4 may achieve this, a higher dose (greater than 10 µg/kg/day) appears to normalise the serum T4 concentrations in three days and maintain the TSH in the target range within two weeks of therapy (<LINK REF="REF-Bakker-1995" TYPE="REFERENCE">Bakker 1995</LINK>). However, the impact on long-term outcomes is controversial. Consequently, one of the major outstanding issues in the management of CHT concerns the amount of the initial levothyroxine dose to be used in the initial treatment of CHT, which may give optimal result in terms of intellectual development. It is thus important to establish the evidence regarding potential benefits of initial dosage requirements in the treatment of CH.</P>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects of the intervention</HEADING>
<P>The use of a high dose in the initial treatment is controversial as it is reported to be associated with behavioural problems, poor visual motor skills and numerical reasoning (<LINK REF="STD-Schwartz-1994" TYPE="STUDY">Schwartz 1994</LINK>; <LINK REF="REF-Rovet-1995" TYPE="REFERENCE">Rovet 1995</LINK>) . There are studies that showed normal outcome in relation to IQ even with lower doses of L-T4 (<LINK REF="STD-Campos-1995" TYPE="STUDY">Campos 1995</LINK>; <LINK REF="REF-Rovet-1995" TYPE="REFERENCE">Rovet 1995</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<IMPORTANCE MODIFIED="2008-11-10 16:06:12 +0100" MODIFIED_BY="Bernd Richter">
<P>Although several reports have been published describing normal IQ values among patients with CHT treated initially with low dosages, more recent studies have demonstrated better outcomes with high L-T4 dosages compared to low dosages.This review tries to establish evidence that high dose treatment of thyroxine in CHT improves neurodevelopmental outcome, growth or behaviour in infants with CHT.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of high versus low dose of initial thyroid hormone replacement for congenital hypothyroidism.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-10 21:29:32 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-10 16:06:47 +0100" MODIFIED_BY="Bernd Richter">
<CRIT_STUDIES>
<P>Randomised controlled clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-10 16:06:47 +0100" MODIFIED_BY="Bernd Richter">
<P>All children diagnosed with congenital hypothyroidism based on a neonatal congenital hypothyroidism screening programmes according to the appropriate diagnostic criteria of the time.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-09-06 23:02:27 +0200" MODIFIED_BY="[Empty name]">
<P>Low dose of levothyroxine (LT-4) of 5 to 9.9 &#956;g/kg/day (standard dose regime) versus high dose of 10 to 15 &#956;g/kg/day (high dose regime).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-10 16:34:13 +0200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-10 16:34:13 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>cognitive development (for example intelligence quotient (IQ), language, visio-spatial processing, selective memory, auditory discrimination, academic achievement, attention and behavioural problems;</LI>
<LI>growth and increased growth rate;</LI>
<LI>adverse effects.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-05-29 13:16:41 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>morbidity;</LI>
<LI>all-cause mortality;</LI>
<LI>development of hyperthyroidism;</LI>
<LI>suppression of thyroid stimulating hormone (TSH),</LI>
<LI>health-related quality of life;</LI>
<LI>costs.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Covariates, effect modifiers and confounders</HEADING>
<UL>
<LI>compliance with the treatment;</LI>
<LI>age treatment is initiated;</LI>
<LI>age at which target range for TSH and thyroxine (T4) are achieved;</LI>
<LI>length of time TSH is maintained in the target range during first year of life.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Timing of outcome measurement</HEADING>
<P>Outcome measurements will be assessed according to the following intervals: <I>
<BR/>
</I>
</P>
<UL>
<LI>short term: less than 12 months;</LI>
<LI>medium term: 1 to 5 years;</LI>
<LI>long-term: more than 5<I> </I>years.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-10 16:10:03 +0100" MODIFIED_BY="Bernd Richter">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-10 16:10:03 +0100" MODIFIED_BY="Bernd Richter">
<P>We used the following sources for the identification of trials:<BR/>
</P>
<UL>
<LI>The <I>Cochrane Library</I>
</LI>
<LI>MEDLINE</LI>
<LI>EMBASE</LI>
</UL>
<P>
<BR/>We also searched databases of ongoing trials: Current Controlled Trials (www.controlled-trials.com - with links to other databases of ongoing trials).<BR/>The described search strategy (see for a detailed search strategy under <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) was used for MEDLINE. For use with EMBASE, <I>The Cochrane Library</I> and the other databases this strategy was slightly adapted.</P>
<P>If additional key words of relevance were detected during any of the electronic or other searches we planned to modify electronic search strategies incorporating these terms. Studies published in any language were included.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-10 16:09:51 +0100" MODIFIED_BY="Bernd Richter">
<P>We tried to identify additional studies by searching the reference lists of included trials and (systematic) reviews, meta-analyses and health technology assessment reports noticed.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-10 21:29:32 +0100" MODIFIED_BY="[Empty name]">
<P>No analysis was possible as only one RCT was included</P>
<STUDY_SELECTION MODIFIED="2008-11-10 21:29:32 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the studies to be assessed further, two reviewers (SN, DA) independently scanned the abstract, title or both sections of every record retrieved. All potentially relevant articles were reviewed as full text. Interrater agreement for study selection was measured using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). Differences were marked and if these studies were later on included, the influence of the primary choice was subjected to a sensitivity analysis. Where differences in opinion existed, they were resolved by the third reviewer (AW). The third reviewer also proof read the review at different stages. If resolving disagreement was not possible, the article was added to those 'awaiting assessment' and authors were contacted for clarification. An adapted QUOROM (quality of reporting of meta-analyses) flow-chart of study selection is attached (<LINK REF="REF-Moher-1999" TYPE="REFERENCE">Moher 1999</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with duplicate publications</HEADING>
<P>In the case of duplicate publications and companion papers of a primary study, we tried to maximise yield of information by simultaneous evaluation of all available data. In cases of doubt, the original publication (usually the oldest version) obtained priority.</P>
</SUBSECTION>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-10 16:30:48 +0100" MODIFIED_BY="Bernd Richter">
<P>For studies that fulfilled inclusion criteria, two authors (SN, DA) independently abstracted relevant population and intervention characteristics using standard data extraction templates (for details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and Appendix 3) with any disagreements being resolved by discussion, or if required by a third party. Any relevant missing information on the trial was sought from the original author(s) of the article, if required.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-09-06 22:06:40 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors (SN, DA) assessed each trial independently (for details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Possible disagreement would be resolved by consensus, or with consultation of a third party in case of disagreement. We planned to explore the influence of individual quality criteria in a sensitivity analysis (see under 'sensitivity analyses'). Interrater agreement for key quality indicators would be calculated using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). In cases of disagreement, the rest of the group would consult and a judgement would be made based on consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-11-10 16:12:20 +0100" MODIFIED_BY="Bernd Richter">
<P>The authors planned to carry out statistical analysis using the Review Manager software. Fixed-effect meta-analysis for combining data in the absence of significant heterogeneity if trials were sufficiently similar would be used. If heterogeneity was found this would have been explored by sensitivity analysis followed by random-effects meta-analysis if required.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2008-11-10 16:13:06 +0100" MODIFIED_BY="Bernd Richter">
<P>Relevant missing data were planned to be obtained from authors, if feasible. Evaluation of important numerical data such as screened, eligible and randomised patients as well as intention-to-treat (ITT) and per-protocol (PP) population were carefully performed. Attrition rates, for example drop-outs, losses to follow-up and withdrawals were investigated. Issues of missing data, ITT and PP were critically appraised and compared to specification of primary outcome parameters and power calculation.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-10-11 10:22:48 +0200" MODIFIED_BY="[Empty name]">
<P>In the event of substantial clinical or methodological or statistical heterogeneity, study results would not be combined by means of meta-analysis. Heterogeneity would be identified by visual inspection of the forest plots, by using a standard &#967;<SUP>2</SUP>-test and a significance level of &#945; = 0.1, in view of the low power of such tests. Heterogeneity would be specifically examined with I<SUP>2</SUP> (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>), where I<SUP>2</SUP> values of 50% and more indicate a substantial level of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If heterogeneity was found, we would attempt to determine potential reasons for it by examining individual study characteristics and those of subgroups of the main body of evidence.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-07-06 22:39:18 +0200" MODIFIED_BY="[Empty name]">
<P>Funnel plots would be used in an exploratory data analysis to assess for the potential existence of small study bias. There are a number of reasons for the asymmetry of a funnel plot, including true heterogeneity, design of studies and publication bias (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>). Therefore, we did not place undue emphasis on this tool (<LINK REF="REF-Lau-2006" TYPE="REFERENCE">Lau 2006</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-06 22:39:11 +0200" MODIFIED_BY="[Empty name]">
<P>Data would be summarised statistically if they were available, sufficiently similar and of sufficient quality. Statistical analysis were performed according to the statistical guidelines referenced in the newest version of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-09-08 21:49:18 +0200" MODIFIED_BY="[Empty name]">
<P>We planned to perform sensitivity analyses in order to explore the influence of the following factors on effect size:<BR/>
</P>
<UL>
<LI>repeating the analysis excluding unpublished studies;</LI>
<LI>repeating the analysis taking account of study quality, as specified above;</LI>
<LI>repeating the analysis excluding any very long or large studies to establish how much they dominate the results;</LI>
<LI>repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.</LI>
</UL>
<P>
<BR/>The robustness of the results would be tested by repeating the analysis using different measures of effects size (relative risk, odds ratio etc.) and different statistical models (fixed- and random-effects models).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-10 16:56:34 +0100" MODIFIED_BY="Bernd Richter">
<STUDY_DESCRIPTION MODIFIED="2008-11-10 16:56:34 +0100" MODIFIED_BY="Bernd Richter">
<SEARCH_RESULTS MODIFIED="2008-11-10 16:56:26 +0100" MODIFIED_BY="Bernd Richter">
<P>The initial search identified 1014 records, from these,13 full publications were identified for further examination. The other studies were excluded on the basis of their abstracts because they were not relevant to the question under study (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details of the amended QUOROM (quality of reporting of meta-analyses) statement) flow-chart of study selection). After screening the full text of the selected publications, only one study finally met the inclusion criteria.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-11-10 16:56:34 +0100" MODIFIED_BY="Bernd Richter">
<P>One trial was included in this review . This reported a sample size of 47 participants and the trial was published in two phases described below.</P>
<P>
<LINK REF="STD-Selva-2002" TYPE="STUDY">Selva 2002</LINK>
</P>
<P>A single centre, randomised controlled trial of 47 infants investigating the effectiveness of three different initial doses in achieving early euthyroid status. The trial had three arms that were randomly assigned to three different starting dosages for the initiation of treatment for congenital hypothyroidism (CHT) detected through a screening programme and confirmed by laboratory investigations. The infants in the first arm received a dose of 37.5 mcg/day (group 1), the second arm 62.5 mcg/day for three days followed by 37.5 mcg/day (group 2) and the third arm 50 mcg/day (group 3). The serum T4, free T4, free T3 and TSH concentrations were measured at baseline before onset of treatment and after 1, 2, 4, 8 and 12 weeks. No changes were made to the initial treatment dose during the first two weeks of treatment but subsequent dosages were altered to maintain the T4 concentrations in the target range using a standard protocol.</P>
<P>
<LINK REF="STD-Selva-2005" TYPE="STUDY">Selva 2005</LINK>
</P>
<P>In the second follow-up phase of the study , children from the above study were followed up between 21 months and 8 years of age to assess their neurodevelopment. Sixteen children were lost to follow-up and the remaining 31 children were assessed. In addition to comparing the neurodevelopmental outcomes of children who received varying initial doses of treatment, a comparison was also made with unaffected sibling controls aged between 43 months and 14 years. All cognitive tests were administered by the same person blinded to the study cohort, disease severity and control participant status. Three different age appropriate cognitive tests were used. Children below four years of age underwent the 'Mullen Scales for Early Learning' test, those between 4 and 6 years were assessed with the 'Wechsler Preschool and Primary Scale of Intelligence- Revised (WPPSI-R)' test and children more than six years were evaluated with the 'Wechsler Intelligence Scale for Children, Third edition (WISC III)' test.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-11-10 16:22:49 +0100" MODIFIED_BY="Bernd Richter">
<P>Twelve studies had to be excluded after careful evaluation of the full publication. Main reasons for exclusion were non-randomisation (for details see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-10 16:28:07 +0100" MODIFIED_BY="Bernd Richter">
<P>In order to assess the risk of bias in the included study, the authors assessed the methodological quality of the included trial using criteria suggested by Jüni for the following dimensions: concealment of allocation; generation of the randomisation sequence; intention-to-treat; and level of blinding reported <LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>. The dimensions, concealment of allocation, generation of the randomisation sequence and intention-to-treat were categorised as adequate, unclear or inadequate which related to a low, unclear or high risk of bias respectively. RCTs were planned to be categorised according to whether double-blinding had been reported or not. The more people blinded to an intervention relates to a decreasing risk of bias to the results.</P>
<ALLOCATION MODIFIED="2008-11-10 16:25:09 +0100" MODIFIED_BY="Bernd Richter">
<P>The included trial stated that allocation was randomised, but did not describe the method of randomisation used. We therefore judged the risk of bias due to the generation of the randomisation sequence as unclear in that trial. Allocation concealment was not described.</P>
</ALLOCATION>
<BLINDING MODIFIED="2008-11-10 16:25:55 +0100" MODIFIED_BY="Bernd Richter">
<P>The trial did not report blinding conditions. </P>
</BLINDING>
<EXCLUSIONS MODIFIED="2008-11-10 16:28:07 +0100" MODIFIED_BY="Bernd Richter">
<P>The trial did not explicitly state that an intention-to-treat analysis was performed. Neither did it state that any participants deviated from the randomised group to which they were assigned to. Therefore we judged the risk of bias to be unclear in this trial. There were 16 participants that were lost to follow-up and these were described. We judged this risk of this bias to be low.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2008-11-06 18:40:04 +0100" MODIFIED_BY="Bernd Richter">
<P>We were unable to identify any selective reporting in the included trial, but did not have any access to the original trial protocols to definitely confirm this; we therefore conclude that there is an unclear risk of bias due to selective reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2008-11-06 18:40:08 +0100" MODIFIED_BY="Bernd Richter">
<P>Participants were selected from a restricted geographical area in proximity to the hospital on the basis of the screening program for identifying CHT babies. This may present a potential risk of bias due to pre-selection of participants.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-10 16:41:44 +0100" MODIFIED_BY="Bernd Richter">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes  </HEADING>
<UL>
<LI>Cognitive development: Participants who were on higher initial dose of 50 mcg/day L-thyroxine had higher full scale IQ scores compared to participants who were on lower initial dose of 37.5mcg/day. Verbal IQ, performance IQ and achievement scores did not differ among the three groups.</LI>
<LI>Growth and increased growth rate: These outcomes were not reported.</LI>
<LI>Adverse effects: No adverse effects were described.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes  </HEADING>
<P>The outcomes morbidity, all-cause mortality, development of hyperthyroidism, suppression of thyroid stimulating hormone (TSH), health-related quality of life and costs were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Covariates, effect modifiers and confounders</HEADING>
<P>Selva 2002 reported full compliance with treatment during the 12 week study follow-up. The age at which treatment was initiated was not reported. Participants on an initial dose of 50 mcg/day (12.5 to 16 mcg/kg/day) (group 3) normalised TSH within two weeks of treatment. Participants on an initial dose of 37.5 mcg/day (9.3 to 12 mcg/kg/day) (group 1) normalised TSH within 12 weeks of treatment. Participants on an initial dose of 62.5 mcg/day for three days followed by 37.5 mcg/day never achieved normal TSH concentrations. Length of time TSH was maintained in the target range during the first year of life was not reported.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-10 16:50:09 +0100" MODIFIED_BY="Bernd Richter">
<P>This review found only one randomised controlled trial which examined the effects of high versus low dose of initial thyroid hormone replacement for congenital hypothyroidism (CHT).</P>
<P>This study had limitations in methodological quality. The trial (<LINK REF="STD-Selva-2002" TYPE="STUDY">Selva 2002</LINK>) was conducted in a single centre comprising of 47 infants with a birth weight between 3 to 4 kg, of which 37% (16 children) were lost to follow-up for the second phase of the study (<LINK REF="STD-Selva-2005" TYPE="STUDY">Selva 2005</LINK>). The trial had three arms that were randomly assigned to three different starting dosages for the initiation of treatment for CHT. Consequently, it did not fully match our initial protocol description of groups as 'low dose' (L-thyroxine (LT-4): 5 to 9.9 &#956;g/kg/day standard dose regime) and 'high dose' (10 to 15 &#956;g/kg/day). For the purpose of this review, we assigned group 1 of the trial as low initial dose based on the calculated dose of 9.3 to 12 &#956;g/kg/day and group 3 of the trial as high initial dose based on the calculated dose of 12.5 to 16 &#956;g/kg/day.</P>
<P>The study found that the serum T4 concentrations reached the recommended target range by three days of treatment in the high dose group but took one week in the low dose group. However, the infants in the high dose group exceeded the upper limits of target range during the first two weeks albeit without any adverse side effects. Similarly, infants in the high dose group had their TSH levels in the normal range by two weeks whereas in the low dose group a normal range was achieved at about 12 weeks.</P>
<P>In the second phase of the study (<LINK REF="STD-Selva-2005" TYPE="STUDY">Selva 2005</LINK>), 16 children were lost to follow-up and the remaining 31 children were assessed between 21 months and 8 years of age for their neurodevelopment. Consequently, different tests were applied to different age groups. The study noted that the full scale IQ scores in the high dose group was significantly higher than in the low dose group. However, verbal IQ, performance IQ and achievement scores did not differ among the three groups</P>
<P>These findings must be interpreted with caution because of several limitations. The number of participants in the trial is very small and authors do not explain how the sample size was calculated. Similarly, they do not describe the randomisation process and allocation concealment and how successful it was except in relation to screening and diagnostic criteria. In the first phase of the study, authors report P-values to illustrate significant differences between high and low dose groups in achieving early euthyroid status but do not provide confidence intervals to estimate the effect size. Similar limitations apply to the second follow-up phase of the study. In addition, different assessment methods were used to assess results at different ages but the results of these assessments were combined in calculating mean scores for the two groups.</P>
<P>Early high dose L-T4 has been reported to close the developmental gap and normalise IQ (<LINK REF="STD-Dubuis-1996" TYPE="STUDY">Dubuis 1996</LINK> ; <LINK REF="STD-Salerno-2002" TYPE="STUDY">Salerno 2002</LINK>, <LINK REF="REF-Simoneau_x002d_Roy-2004" TYPE="REFERENCE">Simoneau-Roy 2004</LINK>), but may be associated with internalising behavioral and concentration problems later in life (<LINK REF="REF-Rovet-1995" TYPE="REFERENCE">Rovet 1995</LINK>). However, a cohort study of 49 adults with early treated CHT and sibling controls showed that no adverse effects of high dose thyroxine were found on measures of memory, attention and behavioural problems (<LINK REF="REF-Oerbeck-2003" TYPE="REFERENCE">Oerbeck 2003</LINK>). A recent retrospective study of high versus low initial doses of L-T4 has found no evidence of sustained overgrowth up to three years of age while a higher dose of L-T4 achieved normalisation of thyroid hormones several months earlier than the lower dose regime (<LINK REF="REF-Jones-2008" TYPE="REFERENCE">Jones 2008</LINK>).</P>
<P>Although results from one randomised controlled trial suggest that a high initial dose in the treatment of CHT is likely to achieve early euthyroid status and improve full-scale IQ scores, the evidence is insufficient to suggest a high dose is more effective than a low dose in the initial management of CHT. Important quality criteria of the trial included were not reported adequately. Therefore, we were unable to make firm conclusions about the quality of the trial based on the evidence that was reported in the trial.</P>
<P>From our review, no conclusive benefit of improved neurodevelopmental outcome can be deduced from the effects of high dose of initial thyroid hormone replacement for congenital hypothyroidism. Although results from one randomised controlled trial found significant improvements in full-scale IQ scores but no significant differences in verbal IQ, performance IQ and achievement scores, this raises the question if there is any real benefit from this intervention while current guidelines nevertheless advocate the use of higher thyroxine treatment doses in CHT.</P>
<P>The importance of establishing clear beneficial outcomes for high dose initial replacement of thyroxine in CHT is therefore of major clinical relevance.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-10 16:54:35 +0100" MODIFIED_BY="Bernd Richter">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-10 16:51:38 +0100" MODIFIED_BY="Bernd Richter">
<P>At present, there is insufficient evidence from randomised controlled trials to evaluate the effectiveness of high versus low dose of initial thyroid hormone replacement for congenital hypothyroidism (CHT). Trials with definite clinical outcomes are essential in evaluating the potential of high dose treatment of CHT. There is still a need for RCTs to evaluate safety and efficacy in the treatment of CHT.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-10 16:54:35 +0100" MODIFIED_BY="Bernd Richter">
<P>This systematic review has identified the need for a well-designed, adequately powered, multi-centred randomised controlled trial on evaluating the effects of high versus low dose of initial thyroid hormone replacement for the treatment of congenital hypothyroidism (CHT). Outcome measures such cognitive development (for example intelligence quotient (IQ), language, visio-spatial processing, selective memory, auditory discrimination, academic achievement, attention and behavioural problems), growth and increased growth rate should be stated and trials be adequately powered to obtain reliable results. At present, with only one RCT, it cannot be stated that high doses of initial thyroid hormone replacement are efficacious and safe in infants with CHT. Therefore, more RCTs are needed to evaluate the effects of high dose versus low dose in the treatment of CHT. We would urge trialists to recognise that the results of individual randomised controlled trials are likely to be included in systematic reviews such as this. They should therefore consider standardising the presentation of outcomes to enable the data to be aggregated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-11-10 21:21:39 +0100" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank Bernd Richter for the useful suggestions and assistance with the review, and the Cochrane group for assisting us with running the search strategies.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-11-06 18:43:18 +0100" MODIFIED_BY="Bernd Richter">
<P>SZE MAY NG and DHULLIPALA ANAND independently selected trials, assessed methodological quality and extracted data. ALAN WEINDLING proof read the review.</P>
<P>The lead author completed the write-up of the review with contributions from the co-authors and acts as guarantor of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-06 18:23:44 +0100" MODIFIED_BY="Bernd Richter">
<STUDIES MODIFIED="2008-11-06 18:20:34 +0100" MODIFIED_BY="Bernd Richter">
<INCLUDED_STUDIES MODIFIED="2008-11-05 16:55:38 +0100" MODIFIED_BY="Bernd Richter">
<STUDY DATA_SOURCE="PUB" ID="STD-Selva-2002" MODIFIED="2008-11-05 16:55:27 +0100" MODIFIED_BY="Bernd Richter" NAME="Selva 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-05 16:55:27 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selva KA, Mandel SH, Rein L, Sesser D, Miyahira R, Skeels M, Nelson JC, La Franchi SH</AU>
<TI>Initial treatment dose of L-thyroxine in congenital hypothyroidism</TI>
<SO>J Peadiatr</SO>
<YR>2002</YR>
<VL>141</VL>
<PG>786-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Selva-2005" MODIFIED="2008-11-05 16:55:38 +0100" MODIFIED_BY="Bernd Richter" NAME="Selva 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-05 16:55:38 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selva KA, Harper A, Downs A, Blasco PA, La Franchi SH</AU>
<TI>Neurodevelopmental outcomes in congenital hypothyroidism: comparison of initial T4 dose and time to reach target T4 and TSH<I> </I>
</TI>
<SO>J Pediatr</SO>
<YR>2005</YR>
<VL>147</VL>
<PG>775-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-06 18:20:34 +0100" MODIFIED_BY="Bernd Richter">
<STUDY DATA_SOURCE="PUB" ID="STD-Bongers_x002d_Schokking-2000" MODIFIED="2008-11-05 16:55:58 +0100" MODIFIED_BY="Bernd Richter" NAME="Bongers-Schokking 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-11-05 16:55:58 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bongers-Schokking JJ, Koot HM, Wiersma D, Verkerk PH, de Muinck Keizer-Schrama SMPF</AU>
<TI>Influence of timing and dose of thyroid hormone replacement on development in infants with congenital hypothyroidism</TI>
<SO>Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>136</VL>
<PG>292-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bongers_x002d_Schokking-2005" MODIFIED="2008-11-05 16:56:13 +0100" MODIFIED_BY="Bernd Richter" NAME="Bongers-Schokking 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-05 16:56:13 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bongers-Schokking JJ, de Muinck Keizer-Schrama SM</AU>
<TI>Influence of timing and dose of thyroid hormone replacement on mental, psychomotor, and behavioral development in children with congenital hypothyroidism</TI>
<SO>J Pediatr</SO>
<YR>2005</YR>
<VL>147</VL>
<PG>768-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campos-1995" MODIFIED="2008-11-05 16:56:36 +0100" MODIFIED_BY="Bernd Richter" NAME="Campos 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-11-05 16:56:36 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campos SP, Sadberg DE, Barric C, Vorhess ML, Mcgillivary MH</AU>
<TI>Outcome of low dose initial thyroxine therapy for congenital hypothyroidism</TI>
<SO>Clinical Pediatrics</SO>
<YR>1995</YR>
<VL>34</VL>
<PG>514-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cassio-2003" MODIFIED="2008-11-05 16:56:48 +0100" MODIFIED_BY="Bernd Richter" NAME="Cassio 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-05 16:56:48 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cassio A, Cacciari E, Cicognani A, Damiani G, Missiroli G, Corbelli E</AU>
<TI>Treatment for congenital hypothyroidism: thyroxine alone or thyroxine plus triiodothyronine?</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>111</VL>
<PG>1055-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiesa-1994" MODIFIED="2008-11-06 18:20:34 +0100" MODIFIED_BY="Bernd Richter" NAME="Chiesa 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-11-06 18:20:34 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiesa A</AU>
<TI>Growth follow-up in 100 children with congenital hypothyroidism before and during treatment</TI>
<SO>The Journal of Pediatric Endocrinology and Metabolism</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>3</NO>
<PG>211-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubuis-1996" MODIFIED="2008-11-05 16:57:47 +0100" MODIFIED_BY="Bernd Richter" NAME="Dubuis 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-11-05 16:57:47 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubuis J, Glorieux J, Richer F, Dussault JH, Vliet GV</AU>
<TI>Outcome of severe congenital hypothyroidism: closing the developmental gap with early high dose levothyroxine therapy</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1996</YR>
<VL>81</VL>
<PG>222-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunn-1996" MODIFIED="2008-11-05 16:58:02 +0100" MODIFIED_BY="Bernd Richter" NAME="Gunn 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-11-05 16:58:02 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunn AJ, Wake M, Cutfield WS</AU>
<TI>High and low dose initial thyroxine therapy for congenital hypothyroidism</TI>
<SO>J Paediatr Child Health</SO>
<YR>1996</YR>
<VL>32</VL>
<PG>242-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salerno-2002" MODIFIED="2008-10-09 21:23:00 +0200" MODIFIED_BY="[Empty name]" NAME="Salerno 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-09 21:23:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salerno M, Militerni R, Bravaccio C, Micillo M, Capalbo D, Di MS, Tenore A</AU>
<TI>Effect of different starting doses of levothyroxine on growth and intellectual outcome at four years of age in congenital hypothyroidism</TI>
<SO>Thyroid</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>1</NO>
<PG>45-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1050-7256 (Print)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-1994" MODIFIED="2008-11-05 16:58:38 +0100" MODIFIED_BY="Bernd Richter" NAME="Schwartz 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-11-05 16:58:38 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz ID, Turner K, Kruger T, Bennet D, Howard CP, Grunt JA</AU>
<TI>Neuropsychological outcome in children with congenital hypothyroidism treated with varying amounts of levothyroxine during first 2 years of life</TI>
<SO>International Pediatrics</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>254-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simoneau_x002d_-Roy-2005" MODIFIED="2008-11-05 16:58:55 +0100" MODIFIED_BY="Bernd Richter" NAME="Simoneau- Roy 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-05 16:58:55 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simoneau-Roy J</AU>
<TI>Cognition and behavior at school entry in children with congenital hypothyroidism treated early with high-dose levothyroxine</TI>
<SO>J Pediatr</SO>
<YR>2004</YR>
<VL>144</VL>
<PG>747-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Touati-1997" MODIFIED="2008-11-05 16:59:08 +0100" MODIFIED_BY="Bernd Richter" NAME="Touati 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-05 16:59:08 +0100" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Touati G, Leger J, Toublanc JC</AU>
<TI>A thyroxine dose of 8 mg/kg per day is appropriate for initial treatment of the majority of infants with congenital hypothyroidism</TI>
<SO>Eur J Pediatr</SO>
<YR>1997</YR>
<VL>156</VL>
<PG>94-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanhole-1997" MODIFIED="2008-10-11 12:47:18 +0200" MODIFIED_BY="[Empty name]" NAME="Vanhole 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-10-11 12:47:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanhole C, Aerssens P, Naulaers G, Casneuf A, Devlieger H, Van Den BG</AU>
<TI>L thyroxine treatment of preterm newborns: Clinical and endocrine effects</TI>
<SO>Pediatr Res</SO>
<YR>1997</YR>
<VL>8</VL>
<PG>87-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-10-11 11:00:52 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-06 18:23:44 +0100" MODIFIED_BY="Bernd Richter">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-06 18:23:44 +0100" MODIFIED_BY="Bernd Richter">
<REFERENCE ID="REF-AAP-1993" MODIFIED="2008-11-06 18:21:56 +0100" MODIFIED_BY="Bernd Richter" NAME="AAP 1993" TYPE="JOURNAL_ARTICLE">
<AU>American Academy of Paediatrics</AU>
<TI>Newborn screening for congenital hypothyrodism: Recommended guidelines</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>91</VL>
<PG>1203-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abusrewil-1988" NAME="Abusrewil 1988" TYPE="JOURNAL_ARTICLE">
<AU>8.Abusrewil SSA, Tyfield L, Savage DCL</AU>
<TI>Serum thyroxine and thyroid stimulating hormone concentrations after treatment of congenital hypothyroidism</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1988</YR>
<VL>63</VL>
<PG>1368-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bakker-1995" MODIFIED="2008-11-05 17:00:31 +0100" MODIFIED_BY="Bernd Richter" NAME="Bakker 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bakker B, Kempers MJ, De Vijdler JJ</AU>
<TI>Dynamics of plasma concentrations of TSH, FT4 and T3 following thyroxine supplementation in congenital hypothyroidism</TI>
<SO>Clinical Endocrinology</SO>
<YR>2002</YR>
<VL>57</VL>
<PG>529-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-1996" MODIFIED="2008-11-05 17:00:37 +0100" MODIFIED_BY="Bernd Richter" NAME="Brown 1996" TYPE="JOURNAL_ARTICLE">
<AU>Brown RS, Bellisaro RL, Botero D</AU>
<TI>Incidence of transient congenital hypothyroidism due to maternal thyrotropin receptor-blocking antibodies in over one million babies</TI>
<SO>Journal of Clinical Endocrnology and Metabolism</SO>
<YR>1996</YR>
<VL>81</VL>
<PG>1147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calaciura-2002" MODIFIED="2008-11-05 17:00:42 +0100" MODIFIED_BY="Bernd Richter" NAME="Calaciura 2002" TYPE="JOURNAL_ARTICLE">
<AU>Calaciura F, Motto RM, Miscio G</AU>
<TI>Subclinical hypothyroidism in early childhood: a frequent outcome of transient neonatal hyperthyrotropinemia</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2002</YR>
<VL>87</VL>
<PG>3209-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1960" NAME="Cohen 1960" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>A coefficient of agreement for nominal scales</TI>
<SO>Educational and Psychological Measurement</SO>
<YR>1960</YR>
<VL>20</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisher-1989" MODIFIED="2008-11-05 17:00:54 +0100" MODIFIED_BY="Bernd Richter" NAME="Fisher 1989" TYPE="JOURNAL_ARTICLE">
<AU>Fisher DA, Foley TP</AU>
<TI>Early treatment of congenital hypothyroidism</TI>
<SO>Journal of Pediatrics</SO>
<YR>1989</YR>
<VL>117</VL>
<PG>211-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Germak-1990" MODIFIED="2008-11-05 17:01:01 +0100" MODIFIED_BY="Bernd Richter" NAME="Germak 1990" TYPE="JOURNAL_ARTICLE">
<AU>Germak JA, Foley TP</AU>
<TI>Longitudinal assessment of L-thyroxine therapy for congenital hypothyroidism</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>117</VL>
<PG>211-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grant-1992" MODIFIED="2008-11-05 17:01:26 +0100" MODIFIED_BY="Bernd Richter" NAME="Grant 1992" TYPE="JOURNAL_ARTICLE">
<AU>Grant DB, Smith I, Fuggle PW, Tokar S, Chapple J</AU>
<TI>Congenital hypothyroidism detected by neonatal screening: relationship between biochemical severity and early clinical features</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1992</YR>
<VL>67</VL>
<PG>87-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gruters-2002" MODIFIED="2008-11-05 17:01:40 +0100" MODIFIED_BY="Bernd Richter" NAME="Gruters 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gruters A, Jenner A, Krude H</AU>
<TI>Long term consequences of congenital hypothyroidism in the era of screening programmes</TI>
<SO>Best Practice Research Clinical Endocrinology and Metabolism</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>369-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haddow-1999" MODIFIED="2008-11-05 17:01:50 +0100" MODIFIED_BY="Bernd Richter" NAME="Haddow 1999" TYPE="JOURNAL_ARTICLE">
<AU>Haddow JE, Palomaki GE, Allan WC</AU>
<TI>Maternal thyroid function during pregnancy and subsequent neuropsychological development of the child</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>549-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heyerdahl-1991" MODIFIED="2008-11-05 17:02:11 +0100" MODIFIED_BY="Bernd Richter" NAME="Heyerdahl 1991" TYPE="JOURNAL_ARTICLE">
<AU>Heyerdahl S, Kase BF, Lie SO</AU>
<TI>Intellectual development in children with congenital hypothyroidism in relation to recommended thyroxine treatment</TI>
<SO>Journal of Pediatrics</SO>
<YR>1991</YR>
<VL>118</VL>
<PG>850-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-04-17 14:05:14 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]</TI>
<SO>In: The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hulse-1984" NAME="Hulse 1984" TYPE="JOURNAL_ARTICLE">
<AU>Hulse JA</AU>
<TI>Outcome for congenital hypothyroidism</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1984</YR>
<VL>59</VL>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2008" MODIFIED="2008-11-06 18:23:04 +0100" MODIFIED_BY="Bernd Richter" NAME="Jones 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jones JH, Gellen G, Paterson WF, Beaton S, Donaldson MD</AU>
<TI>Effect of high versus low initial doses of L-thyroxine for congenital hypothyroidism on thyroid function and somatic growth</TI>
<SO>Arch Dis Child</SO>
<YR>2008</YR>
<VL>93</VL>
<NO>11</NO>
<PG>940-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" MODIFIED="2008-11-05 17:03:01 +0100" MODIFIED_BY="Bernd Richter" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M.</AU>
<TI>Systematic reviews in health care:Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-LaFranchi-1999" NAME="LaFranchi 1999" TYPE="JOURNAL_ARTICLE">
<AU>LaFranchi S</AU>
<TI>Thyroid function in the preterm infant</TI>
<SO>Thyroid</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>1</NO>
<PG>71-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1050-7256 (Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lau-2006" MODIFIED="2008-11-05 17:03:20 +0100" MODIFIED_BY="Bernd Richter" NAME="Lau 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I</AU>
<TI>The case of the misleading funnel plot</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>333</VL>
<PG>597-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1999" NAME="Moher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF</AU>
<TI>Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9193</NO>
<PG>1896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murphy-1986" MODIFIED="2008-11-05 17:03:46 +0100" MODIFIED_BY="Bernd Richter" NAME="Murphy 1986" TYPE="JOURNAL_ARTICLE">
<AU>Murphy G, Hulse JA, Jackson D</AU>
<TI>Early treated hypothyroidism:development at 3 years</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1986</YR>
<VL>61</VL>
<PG>761-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ng-2004" NAME="Ng 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ng PC, Lee CH, Lam CW, Ma KC, Fok TF, Chan IH, Wong E</AU>
<TI>Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants</TI>
<SO>Archives of Disease in Childhood Fetal Neonatal Ed</SO>
<YR>2004</YR>
<VL>89</VL>
<NO>2</NO>
<PG>F119-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1359-2998 (Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oerbeck-2003" MODIFIED="2008-11-05 17:04:02 +0100" MODIFIED_BY="Bernd Richter" NAME="Oerbeck 2003" TYPE="JOURNAL_ARTICLE">
<AU>Oerbeck B, Sundet K, Kase BF, Heyerdahl S</AU>
<TI>Congenital hypothyroidism: influence of disease severity and L-thyroxine treatment on intellectual, motor and school-associated outcomes in young adults</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>112</VL>
<PG>923-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rovet-1995" MODIFIED="2008-11-05 17:04:09 +0100" MODIFIED_BY="Bernd Richter" NAME="Rovet 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rovet JF, Ehrlich RM</AU>
<TI>Long term effects of L-thyroxine therapy for congenital hypothyrodism</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>126</VL>
<PG>380-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rovet-2002" MODIFIED="2008-11-05 17:04:15 +0100" MODIFIED_BY="Bernd Richter" NAME="Rovet 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rovet JF</AU>
<TI>Congenital hypothyroidism: an analysis of persisting deficits and associated factors</TI>
<SO>Child Neuropsychology</SO>
<YR>2002</YR>
<VL>8</VL>
<PG>150-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salerno-1999" NAME="Salerno 1999" TYPE="JOURNAL_ARTICLE">
<AU>Salerno M, Militerni R, Di Maio S, Bravaccio C, Gasparini N, Tenore A</AU>
<TI>Intellectual outcome at 12 years of age in congenital hypothyroidism</TI>
<SO>European Journal of Endocrinology</SO>
<YR>1999</YR>
<VL>141</VL>
<NO>2</NO>
<PG>105-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0804-4643 (Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Simoneau_x002d_Roy-2004" MODIFIED="2008-09-08 22:16:21 +0200" MODIFIED_BY="[Empty name]" NAME="Simoneau-Roy 2004" TYPE="JOURNAL_ARTICLE">
<AU>Simoneau-Roy J, Marti S, Deal C, huot C, Robaey P, Van Vliet G</AU>
<TI>Cognition and behaviour at school entry with children with congenital hypothyroidism treated early with high dose levothyroxine</TI>
<SO>J Pediatr</SO>
<YR>2004</YR>
<VL>144</VL>
<PG>747-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Song-2001" NAME="Song 2001" TYPE="JOURNAL_ARTICLE">
<AU>Song SI, Daneman D, Rovet J</AU>
<TI>The influence of etiology and treatment factors on intellectual outcome in congenital hypothyroidism</TI>
<SO>Journal of Developmental Behavioural Pediatrics</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>6</NO>
<PG>376-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0196-206X (Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" NAME="Sterne 2001" TYPE="BOOK_SECTION">
<AU>Sterne JAC, Egger M, Davey Smith G</AU>
<TI>Investigating and dealing with publication and other biases</TI>
<SO>Systematic Reviews in Health Care; Meta-analysis in Context</SO>
<YR>2001</YR>
<PG>189-208</PG>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Working-group-1999" MODIFIED="2008-11-05 17:05:05 +0100" MODIFIED_BY="Bernd Richter" NAME="Working group 1999" TYPE="JOURNAL_ARTICLE">
<AU>Working group on neonatal screening of the European Society of Paediatric Endocrinology</AU>
<TI>Revised guidelines for neonatal screening programmes for primary congenital hypothyroidism</TI>
<SO>Horm Res</SO>
<YR>1999</YR>
<VL>52</VL>
<PG>49-52</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-10 15:41:33 +0100" MODIFIED_BY="Bernd Richter">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-10 15:37:39 +0100" MODIFIED_BY="Bernd Richter" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Study details" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Publication details" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Stated aim of study">
<INCLUDED_CHAR MODIFIED="2008-11-10 15:35:28 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Selva-2002">
<CHAR_METHODS MODIFIED="2008-09-06 21:57:07 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-10 15:29:01 +0100" MODIFIED_BY="Bernd Richter">
<P>47 babies with congenital hypothyroidism detected by newborn screening</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-06 21:54:03 +0200" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to 3 dosage arms of 37.5 mcg/day (group 1), 62.5 mcg/day for 3 days followed by 37.5 mcg/day (group 2) and 50 mcg/day (group 3)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-06 22:19:36 +0200" MODIFIED_BY="[Empty name]">
<P>1) Time to normalisation of TSH during the first 12 weeks of CHT treatment</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2008-10-12 16:17:56 +0200" MODIFIED_BY="[Empty name]">
<P>Initial dose of 50mcg/day (12-17mcg/kg/day) (group 3) normalised TSH by 2 weeks of treatment. Initial dose of 37.5mcg/day (9-3-12 mcg/kg/day) (group 1) normalised TSH by 12 weeks of treatment. Initial dose of 62.5mcg/day for 3 days followed by 37.5 mcg/day never achieved normal TSH concentrations</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-09-06 21:56:43 +0200" MODIFIED_BY="[Empty name]">
<P>J Pediatr 2002; 141:786-92</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-10 15:35:28 +0100" MODIFIED_BY="Bernd Richter">
<P>Quote "The first objective of our study was to determine the ideal replacement dose of L-thyroxine in infants with CH as judged by the time course of rise in T4 and free T4 and fall in TSH, by using 3 treatment arms. A second objective was to compare the rise in T4 and free T4 and fall in TSH between mild and severe cases of CH within each treatment group. A third objective was to reexamine the &#8220;target&#8221; T4 and free T4 range in the first 2 weeks of therapy, with the use of the above regimens, as judged by the corresponding TSH concentrations".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-10 15:37:39 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Selva-2005">
<CHAR_METHODS MODIFIED="2008-11-10 15:37:09 +0100" MODIFIED_BY="Bernd Richter">
<P>Randomised controlled trial. follow-up study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-10 15:29:47 +0100" MODIFIED_BY="Bernd Richter">
<P>47 babies with congenital hypothyroidism detected by newborn screening</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-06 22:02:20 +0200" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to 3 dosage arms of 37.5 mcg/day (group 1), 62.5 mcg/day for 3 days followed by 37.5 mcg/day (group 2) and 50 mcg/day (group 3)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-06 22:02:12 +0200" MODIFIED_BY="[Empty name]">
<P>Neurodevelopment assessment using Mullen Scales of Early learning, Weschler Preschool and Primary Scale of Intelligence-revised, Weschler Intelligence Scale for Children, Wide Range of Acheivement Test and Child Behavioural Checklist</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2008-10-12 16:18:01 +0200" MODIFIED_BY="[Empty name]">
<P>Participants who were on higher initial dose of 50mcg/day L-thyroxine had higher full scale IQ scores compared to participants who were on lower initial dose of 37.5mcg/day. verbal IQ, performance IQ and achievement scores did not differ among the three groups.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-09-06 21:56:47 +0200" MODIFIED_BY="[Empty name]">
<P>J Pediatr 2005; 147:775-80</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-10 15:37:39 +0100" MODIFIED_BY="Bernd Richter">
<P>Quote "Our goal was to compare neurodevelopmental outcomes, particularly cognition, academic achievement, and attention/behavior, among the 3 treatment groups. In addition, we investigated the effect of CH severity, differences (if any) between CH subjects and their unaffected siblings, and the effect of the timing of thyroid function normalization on neurodevelopmental outcomes in all treatment cohorts".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-10 15:41:33 +0100" MODIFIED_BY="Bernd Richter" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:38:16 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Bongers_x002d_Schokking-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:38:16 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a non-randomised clinical controlled trial studying the timing and dose of thyroid hormone replacement on development in infants with CHT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:38:23 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Bongers_x002d_Schokking-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:38:23 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a non-randomised clinical controlled trial studying the timing and dose of thyroid hormone replacement on development in infants with CHT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:38:36 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Campos-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:38:36 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a non-randomised clinical controlled trial studying the outcome of low dose initial thyroxine therapy for CHT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:39:01 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Cassio-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:39:01 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a randomised controlled clinical trial of thyroxine (T4) plus triiodothyronine (T3) versus T4 alone in CH patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:39:11 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Chiesa-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:39:11 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a non-randomised clinical controlled trial studying the growth of children with CHT before and during treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:39:20 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Dubuis-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:39:20 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a non-randomised clinical controlled trial studying the outcome of severe CHT using early high dose T4 therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:39:26 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Gunn-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:39:26 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a non-randomised clinical controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:39:34 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Salerno-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:39:34 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a non-randomised clinical controlled trial studying the effect of different starting doses of T4 on growth and outcome at four years of age in CHT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-11 11:08:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwartz-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-11 11:08:54 +0200" MODIFIED_BY="[Empty name]">
<P>This is a non-randomised clinical controlled trial studying the outcome in children with CHT treated with varying amounts of T4 during first 2 years of life. This does not fulfill the objective of the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:39:41 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Simoneau_x002d_-Roy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:39:41 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a non-randomised clinical controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:39:46 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Touati-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:39:46 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a non-randomised clinical controlled trial. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-10 15:39:52 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Vanhole-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-10 15:39:52 +0100" MODIFIED_BY="Bernd Richter">
<P>This is a randomised clinical controlled trial looking at replacement thyroxine therapy in hypothyroxinaemia of prematurity and not in congenital hypothyroidism. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CHT = congenital hypothyroidism</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-10-11 11:00:52 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-11-10 15:30:21 +0100" MODIFIED_BY="Bernd Richter">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-09-06 22:04:25 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-06 22:04:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selva-2002">
<DESCRIPTION>
<P>Described as randomised, but no details of method given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-06 22:04:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selva-2005">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-09-06 22:06:06 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-06 21:56:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selva-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-06 22:06:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selva-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-09-06 22:05:08 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-06 22:05:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selva-2002">
<DESCRIPTION>
<P>Did not report blinding of investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-09-06 22:05:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selva-2005">
<DESCRIPTION>
<P>Did not report blinding of investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-11-10 15:28:14 +0100" MODIFIED_BY="Bernd Richter" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-10 15:28:14 +0100" MODIFIED_BY="Bernd Richter" RESULT="YES" STUDY_ID="STD-Selva-2002">
<DESCRIPTION>
<P>Described as no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-09-06 22:08:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Selva-2005">
<DESCRIPTION>
<P>16 participants were lost to follow up and reasons were described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-09-06 22:09:39 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-06 22:09:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selva-2002">
<DESCRIPTION>
<P>Unable to identify any selective reporting in the included trial as did not have any access to the original trial protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-09-06 22:08:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selva-2005">
<DESCRIPTION>
<P>Unable to identify any selective reporting in the included trial, but did not have any access to the original trial protocols</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-11-10 15:30:21 +0100" MODIFIED_BY="Bernd Richter" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 15:28:51 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Selva-2002">
<DESCRIPTION>
<P>Participants were selected from a restricted geographical area in proximity to the hospital on the basis of the screening program for identifying congenital hypothyroidism babies. This may present a potential risk of bias due to pre-selection of participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 15:30:21 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Selva-2005">
<DESCRIPTION>
<P>Participants were selected from a restricted geographical area in proximity to the hospital on the basis of the screening program for identifying congenital hypothyroidism babies. This may present a potential risk of bias due to pre-selection of participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-11 09:54:46 +0100" MODIFIED_BY="Bernd Richter">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-11 09:54:46 +0100" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2008-04-17 13:47:11 +0200" MODIFIED_BY="[Empty name]">Study populations</TITLE>
<TABLE COLS="8" ROWS="2">
<TR>
<TD>
<P>study ID</P>
</TD>
<TD>
<P>intervention</P>
</TD>
<TD>
<P>[n] screened</P>
</TD>
<TD>
<P>[n] randomised</P>
</TD>
<TD>
<P>[n] safety</P>
</TD>
<TD>
<P>[n] ITT</P>
</TD>
<TD>
<P>[n] finishing study</P>
</TD>
<TD>
<P>comments</P>
</TD>
</TR>
<TR>
<TD>
<P>Selva 2002</P>
</TD>
<TD>
<P>Intervention (I): L-thyroxine 50 mcg/day</P>
<P>Control1 (C1): L-thyroxine 37.5mcg/day</P>
<P>Control 2 (C2): loading dose 50 mcg/day for 3 days,<BR/>followed by 37.5mcg/day</P>
</TD>
<TD>
<P>I: nr</P>
<P>C1: nr</P>
<P>C2: nr</P>
</TD>
<TD>
<P>I: 15</P>
<P>C1: 15</P>
<P>C2: 17</P>
<P>Total: 47</P>
</TD>
<TD>
<P>I: nr</P>
<P>C1: nr</P>
<P>C2: nr</P>
</TD>
<TD>
<P>I: nr</P>
<P>C1: nr</P>
<P>C1: nr</P>
</TD>
<TD>
<P>I: 15</P>
<P>C1: 15</P>
<P>C2: 17</P>
<P>Total: 47</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>nr = not reported</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-05-29 13:47:42 +0200" MODIFIED_BY="[Empty name]"/>
<FIGURES MODIFIED="2008-11-10 16:15:15 +0100" MODIFIED_BY="Bernd Richter">
<FIGURE FILENAME="ng quorom flow.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2008-11-10 16:15:15 +0100" MODIFIED_BY="Bernd Richter" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Amended QUOROM (quality of reporting of meta-analyses) statement) flow-chart of study selection</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-11 09:57:01 +0100" MODIFIED_BY="Bernd Richter">
<APPENDIX ID="APP-01" MODIFIED="2008-11-06 17:48:44 +0100" MODIFIED_BY="Bernd Richter" NO="1">
<TITLE MODIFIED="2008-04-17 13:41:55 +0200" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-06 17:48:44 +0100" MODIFIED_BY="Bernd Richter">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms were free text terms; exp = exploded MeSH: Medical Subject Heading (Medline medical index term); the dollar sign ($) stands for any character(s); the question mark (?) = substitute for one or no characters; ab = abstract; ti = titel; ot = original titel; pt = publication type; sh = MeSH: Medical subject heading (MEDLINE medical index term); adj = adjacency.<BR/>
<BR/>1.exp Congenital Hypothyroidism/<BR/>2.(congenital adj3 (myx?edema$ or hypothyroidism$)).tw,ot.<BR/>3.1 or 2<BR/>
<BR/>4.Randomized Controlled Trial.pt.<BR/>5.Controlled Clinical Trial.pt.<BR/>6.Randomized Controlled Trials.sh.<BR/>7.Random Allocation.sh.<BR/>8.Double-Blind Method.sh.<BR/>9.Single-Blind Method.sh.<BR/>10.or/4-9<BR/>11.clinical trial.pt.<BR/>12.Clinical Trials.sh.<BR/>13.(clinic$ adj25 trial$).tw,kf,ot.<BR/>14.((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw,kf,ot.<BR/>15.Placebos.sh.<BR/>16.placebo$.tw,kf,ot.<BR/>17.random$.tw,kf,ot.<BR/>18.Research Design.sh.<BR/>19.(latin adj square).tw,kf,ot.<BR/>20.or/11-19<BR/>21.comparative study.pt.<BR/>22.Evaluation Studies.sh.<BR/>23.Follow-up Studies.sh.<BR/>24.Prospective Studies.sh.<BR/>25.(control$ or prospectiv$ or volunteer$).tw,kf,ot.<BR/>26.Cross-Over Studies.sh.<BR/>27.or/21-26<BR/>28.10 or 20 or 27<BR/>29.limit 28 to animals<BR/>30.limit 28 to humans<BR/>31.29 not 30<BR/>32.28 not 31<BR/>
<BR/>33.exp "Review Literature"/<BR/>34.exp Technology Assessment, Biomedical/<BR/>35.exp Meta-Analysis/<BR/>36.meta-analysis.pt.<BR/>37.((review$ or search$) adj10 (literature or medical database$ or medline or pubmed or<BR/>embase or cochrane or cinhal or psychinfo or psychlit or healthstar or biosis or current<BR/>content$ or systemat$)).tw,kf,ot.<BR/>38.hta.tw,kf,ot.<BR/>39.(health technology adj6 assessment$).tw,kf,ot.<BR/>40.(meta analy$ or metaanly$ or meta?analy$).tw,kf,ot.<BR/>41.or/33-40<BR/>42.32 or 41<BR/>
<BR/>43.3 and 42<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-11-11 09:57:01 +0100" MODIFIED_BY="Bernd Richter" NO="2">
<TITLE MODIFIED="2008-04-17 13:42:07 +0200" MODIFIED_BY="[Empty name]">Baseline characteristics</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-11 09:57:01 +0100" MODIFIED_BY="Bernd Richter">
<TABLE COLS="2" ROWS="7">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>Selva 2002</P>
</TH>
</TR>
<TR>
<TD>
<P>Intervention: L-thyroxine 50 mcg/day, n=15</P>
<P>Control1: L-thyroxine 37.5mcg/day, n=15</P>
<P>Control 2: loading dose 50 mcg/day for 3 days, followed by 37.5mcg/day, n=17</P>
</TD>
<TD>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Sex [female% / male%]<BR/>
</P>
</TD>
<TD>
<P>I1: nr</P>
<P>C1: nr</P>
<P>C2: nr</P>
<P>Total: 47<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Age [mean days (SD)]</P>
</TD>
<TD>
<P>I1: nr, &lt; 1 year</P>
<P>C1: nr, &lt; 1 year</P>
<P>C2: nr, &lt; 1 year</P>
<P>Total: mean age at which newborn screenign test was performed: 1.6 ( SD 1.4) days</P>
</TD>
</TR>
<TR>
<TD>
<P>Ethnic groups [%]<BR/>
</P>
</TD>
<TD>
<P>I1: nr</P>
<P>C1: nr</P>
<P>C2: nr</P>
</TD>
</TR>
<TR>
<TD>
<P>Notes<BR/>
</P>
</TD>
<TD>
<P>all infants recruited were enrolled in the study after detection by the Northwest Regional Newborn Screening Program</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<I>Footnotes</I>
</P>
<P>nr = not reported</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>